Clinical trials: Telangiectasia
Epistaxis
NOrth American Study for the Treatment of Recurrent epIstaxis With DoxycycLine: The NOSTRIL Trial
The purpose of this research study is to determine whether Doxycycline can be used to control nosebleeds (epistaxis) for patients with Hereditary Hemorrhagic Telangiectasia (HHT).
- Trial name
- NOSTRIL (NCT04167085)
- Testing
- Doxycycline
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University of California, Los Angeles
Hemorrhagic Hereditary Telangiectasia (HHT)
Efficacy and Safety of a 0.1% Tacrolimus Nasal Ointment as a Treatment for Epistaxis in Hemorrhagic Hereditary Telangiectasia (HHT)
The recognized manifestations of HHT are all due to abnormalities in vascular structure. Epistaxis due to telangiectases formation is spontaneous, very variable, recurrent in 90% of patients, and associated with severe anemia in…
- Trial name
- TACRO (NCT03152019)
- Testing
- Protopic® (Tacrolimus) 0.1% ointment
- Where
- 3 sites in France
- Volunteers
- 50 people
- Sponsor
- Hospices Civils de Lyon